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DOI 10.1016/j.stem.2009.01.002Unlike most other broadly disseminated
tools of biotechnology, moral, legal, polit-
ical, and economic factors impact whether
and how hESC lines reach the researchers
who need them. On August 9, 2001, Pres-
ident George W. Bush announced that
federal funding for hESC research would
be limited to already-existing cell lines.
That policy constrained academic scien-
tists by hampering their ability to freely
create or select research materials (Rao,
2006). Since Bush’s announcement, there
have been anecdotal reports about how
federal and state policies might hinder or
aid this promising area of research (Long-
aker et al., 2007). Yet no research has
described when, where, and to whom
these lines go when they leave major
repositories, and little empirical evidence
examines the effects variation in state-
level policies might exert on researchers’
use of hESC lines. To address these ques-
tions, we use materials transfer agree-
ments (MTAs) to track shipments of 1662
vials of stem cells from two major U.S.-
based repositories, WiCell Research Insti-
tute (WiCell) and the Harvard Stem Cell
Institute (HSCI). We begin by documenting
aggregate trends in the global distribution
of hESC lines. Next, we analyze interstate
differences in shipment rates by biomed-
ical research capacity, indexed by cumu-
lative NIH funding levels, and state-level
hESC policies. We find that predictions
about the chilling effect of restrictive
federal policies are oversimplified. This
report provides the first systematic
description of global and national flows
of hESC lines from two major U.S.-based
repositories.
Distribution rates and patterns for hESC
lines can serve as a proxy for research
activity in this new field. Flows of cell
lines can indicate how outside factors
help shape the trajectory of biomedical
research. In turn, these factors have
important consequences for scientific
collaboration,policymaking, and the even-
tual use of stem cell therapies. Further-
more, the lines available from WiCell are
approved for use with U.S. federal funds
while the lines fromHSCI arenot,providing
an interesting point of comparison.
Many sources of funding also impact
research capacity. These include
industry-sponsored research, founda-
tions, philanthropy, and state responses
such as economic development efforts.
Systematic data on such funding sources
are difficult to obtain, and thus, we use NIH
expenditures to ensure the breadth and
comparability of our analyses. Though by
no means the only measure of a state’s
research capacity, we treat NIH funding
as an important, though rough, proxy for
state-level biomedical research capacity.
We find evidence of a complex relation-
ship among federal and state policies,
state-level research capacity, anddemand
for cell lines. National proscriptions do
not exert equal influence on the behavior
of scientists in different states. State
attempts to enhance scientific efforts by
policy fiat do not uniformly spur demand
for lines absent existing research capacity.
Past success in NIH funding can make
states without supportive policies impor-
tant sites for stem cell science. In sum,
varied state-level polices can shape and
underpin national growth in demand for
cell lines.
The exchange of research tools
between owners and users are often
bound by material transfer agreements
(MTAs), legal documents that govern the
use of reagents and cell lines. We obtained
information about MTAs executed bet-
ween 2000 and 2007 by WiCell and HSCI
and document the number of vials in total
and from the individual sources over time
as well as to what state or nation. Each
MTA was categorized by destination and
cell line. The resulting data set consisted
of 724 MTAs issued by WiCell between
2000 and 2007 and 232 MTAs issued by
HSCI between 2004 and 2007. WiCell
appears to execute one MTA for every
vial it ships, while Harvard issues multiple
lines under one agreement. The numbers
of vials shipped are 743 and 919, respec-
tively. In total, the data tracks the distribu-
tion of 1662 vials of 38 different hESC
lines. The fact that the HSCI has distrib-
uted nearly 200 more vials than WiCell in
about half the time might be explained by
the fact that, until the fall of 2005, the
cost for a WiCell line was $5,000, while
users of lines from HSCI were charged
the cost of shipping.
Thirty-six different nations on six conti-
nents received at least one vial distributed
by WiCell or HSCI. European, North Amer-
ican, and Asian nations are well repre-
sented. Shipments also went to Australia,
South America, and Africa. Most cell lines
shipped within the United States, where
scientists have received slightly more
than 64% (1077) of the vials. The remain-
ing 585 were distributed to researchers
in other nations. HSCI distributed more
vials abroad than did WiCell, while WiCell
distributed more vials within the U.S. As
Figure 1A shows, overall U.S. demand
was nearly twice as high as for the rest of
the world. Given the research capacity
usually associated with the United States
as well as the increased state level activity,
this finding is not surprising. However, part
of the difference may be due to non-U.S.
labs with access to non-US lines. Informa-
tion about which lines are included in
our data set can be found in the Supple-
mental Data.
Figure 1B shows that the number of
vials distributed increased over time,
and the distribution pattern follows that
characteristic of new technologies: the
well-known ‘‘S-shaped’’ curve that tracks
market saturation for new technologies
(Rogers, 2005). The changes we observe
in that curve appear to coincide with
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during the period from 2003 to 2004
corresponds to HSCI’s first shipments in
April 2004, and the flattening of the WiCell
distribution during this time might be due
to HSCI charging only shipping costs
for cell lines. That policy made HSCI
materials significantly cheaper. In return,
WiCell fueled a sharp overall increase in
2005 by dramatically cutting its fees.
A $16 million NIH grant to WiCell as
the curator of federally approved lines
allowed the institute to lower the price of
a vial to $500 in October, 2005 (Wisconsin
Technology Network). WiCell’s lines are
eligible for federal funding, and the pros-
pect of broader research support
combined with a more competitive per
vial price may have made them more
desirable, flattening demand for HSCI
lines. The overall decrease in demand
for the period from 2006 to 2007 may be
explained by the fact that more
researchers obtained lines from other
sources or became efficient at establish-
ing stocks of their own. Thus, our data
may under-represent actual use of
hESC lines in both U.S. and other jurisdic-
tions.
Extending our data into 2008 might
show even further decrease in demand
due to the new and relatively accessible
method of deriving induced pluripotent
stem (iPS) cells. Some reports indicate
that in the first several months they were
available, requests for gene delivery
vectors for iPS cell protocols were signifi-
cant: 704 individuals from 142 institutions
requested materials from Thomson and
colleagues (Yu et al., 2007), and 514 indi-
viduals from 113 institutions requested
vectors from Yamanaka and colleagues
(Takahashi et al., 2007). Nevertheless,
the overall pattern of cell line shipments
suggests that hESC research is alive and
growing in the U.S.
The aggregate number of cell line ship-
ments by state is an indicator of research
activity, but the date when scientists in
a state began work in the field is also
important. First mover advantage can be
a key to victory in scientific-priority races;
thus, those states that entered the game
early may reap the most scientific gains
(Merton, 1957). The states with earlier ship-
ment dates typically receive more lines
overall. Only four states (California, Illinois,
Michigan, and North Carolina) received at
least one line prior to August 9, 2001. Cal-
ifornia went on to develop the nation’s
largest stem cell infrastructure, but all four
first movers are in the top quartile for total
shipments. Forty states and the District of
Columbia (henceforth referred to as states)
had received at least one vial by the end of
2007, when our data sets stops.
Figure 2 categorizes states on three
dimensions: (1) the absolute number of
hESC vials they receive, (2) cumulative
NIH obligations to research institutions in
the state, and (3) the number of vials
received per $10 million of NIH funding.
The final measure provides a normalized
indication of relative demand intensity
across states. In all cases, we treat the
top quartile as a cutoff point. We dub
states that fall in the top 25% for hESC
shipments as ‘‘high vial.’’ Similarly, we
designated states as ‘‘high NIH’’ based
on whether they fell above or below the
top quartile of cumulative NIH funding
and ‘‘high normalized’’ based on whether
they fell above or below the top quartile of
the normalized data. While not perfect,
these binary distinctions allow us to
examine contingent differences in state
level use of hESC materials (Additional
methodological details can be found in
the Supplemental Data).
Because the variation in cell line ship-
ments is significantly smaller than the
variation in NIH funding, normalized data
are suspect for global comparisons. For
example, West Virginia, Nevada, Ken-
tucky, and Maine all appear in the top
normalized quartile. Their rankings are
more attributable to the small amount of
NIH funding each receives than actual
demand for cell lines. Therefore, focusing
on absolute rather than relative numbers
of shipments speaks more directly to the
interests of scientists and policymakers.
We turn to normalized measures only
when they distinguish among states that
are relative peers in terms of absolute
demand and NIH support.
Dramatic interstate variation in demand
appears to characterize the overall growth
of U.S. stem cell shipments between 2000
and 2007. On average, states received
20.78 vials (±52.7). Ten states have
received 20 or more vials of cell lines
from either of the two sources since
2000, and four (California, Massachu-
setts, Maryland, and New York) have
received more than fifty vials each. These
states account for 64% of U.S. hESC
shipments and also are the top four recip-
ients of NIH funding (Figure 2).
Despite a patchwork of policies, states
with a wide range of federally supported
biomedical research contribute to the
demand for lines. State-level hESC
research policies play a mixed role in this
story. In order to examine the relationship
between policy and demand for cell lines
at the state level, we define states that
have passed legal measures that explicitly
reduce barriers for researchers or appro-
priated money to support hESC research
as ‘‘first category’’ states. States that do
not meet either of these criteria are defined
as ‘‘second category’’ states, which
reflect a range of approaches to stem
hESC research. Our binary distinction,
thus, does little to account for the broad
spectrum of state policies, ranging from
aggressive constitutional action support-
ing research (California) to legislative
silence, thus not deviating from federal
policy (Minnesota). More restrictive
approaches include Pennsylvania, which
Figure 1. Distribution Patterns of hESC
Lines Tracked by MTA Agreements
(A) Number of vials of hESCs distributed: the
aggregate distribution of vials by WiCell, by HSCI,
and in total within the USA, in the rest of the world,
and overall.
(B) Number of vials of hESC distributed over time in
total, by WiCell and by HSCI.
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on embryos, and South Dakota, which
criminalizes hESC research. In some
states, funding and legislative criteria
conflict with each other. For example,
Wisconsin—the home of WiCell—funds
hESC research, yet passed two bills
proscribing it. Neither became law.
While simple, our binary distinction
provides some analytic purchase. Figure 2
shows eleven first category states. While
many of these states are also among the
leaders on our measure of research
capacity, not all top the charts in NIH
funding. Likewise, some first category
states (Missouri and New Jersey) are not
in the top quartile (greater than 16 vials)
in terms of stem cell shipments. In
contrast, Ohio, a second category state,
has been the destination for relatively
few vials. Yet, Ohio is among the top quar-
tile for NIH funding. This state has signifi-
cant research capacity and has done little
to expand opportunities for hES research.
The point we take from this picture is that
local political efforts may smooth entry
into this controversial field for researchers
under some conditions, but other factors
are important.
California, Massachusetts, Maryland,
and New York lead in absolute numbers
of hESC line shipments, and all have
exceptionally high levels of NIH funding.
However, Texas (fifth) and Pennsylvania
(tied for sixth) exhibit less consistent
trends. Both states rank high in terms of
research capacity and absolute numbers
of cell shipments. But normalized mea-
sures reveal a difference, as Pennsylvania
receives fewer cell lines per $10 million of
NIH funding. Neither is a first category
state with supportive policy environ-
ments. But it does not mean the policy
environments are equivalent. Scientists
in Texas face no barriers to their research
beyond those imposed by federal policy.
A longstanding Pennsylvania law prohibits
nontherapeutic research on any unborn
child—defined as a human organism
from fertilization until birth—making it
more restrictive than federal policy.
(Pennsylvania Statute, 1982). The relative
difference in shipment rates between
Pennsylvania and Texas may reflect the
dampening effect more restrictive policies
can have on demand for cell lines.
Not surprisingly, of the 13 states in the
top quartile receiving shipments, four first
category states (California, Massachu-
setts, Maryland, and New York) receive
the most vials and most NIH funding.
Thirty-eight states received fewer than
16 vials, placing them in the bottom three
quartiles in terms of shipments. It is inter-
esting to note that four of those states
State State Abbreviations Cumulative NIH Funding Normalized Data
California CA 322 23,352,310,000 0.1378879
Massachusetts MA 204 16,730,780,000 0.1219309
Maryland MD 96 38,357,500,000 0.0250277
New York NY 69 15,562,800,000 0.0443365
Texas TX 49 8,586,019,000 0.0570695
Pennsylvania PA 41 10,689,210,000 0.0383564
Wisconsin WI 41 2,852,422,000 0.1437375
Illinios IL 25 5,155,887,000 0.0484883
Virginia VA 24 2,723,974,000 0.0881066
Washington WA 23 5,950,824,000 0.0386501
Connecticut CT 19 3,452,984,000 0.0550249
Michigan MI 18 4,339,397,000 0.0414804
North Carolina NC 16 8,002,327,000 0.0199942
Georgia GA 15 2,622,673,000 0.0571936
Kentucky KY 11 911,117,000 0.1207309
Minnesota MN 11 3,279,572,000 0.033541
Florida FL 10 2,498,809,000 0.0400191
Missouri MO 9 3,958,758,000 0.0227344
New Jersey NJ 7 1,940,381,000 0.0360754
Ohio OH 7 5,069,121,000 0.0138091
Utah UT 7 1,232,589,000 0.056791
Colorado CO 6 2,598,300,000 0.023092
Tennessee TN 6 2,803,883,000 0.0213989
Alabama AL 5 2,360,492,000 0.021182
Hawaii HI 5 429,267,000 0.1164776
Maine ME 5 504,929,000 0.0990238
Kansas KS 4 617,752,000 0.0647509
Oregon OR 4 1,970,249,000 0.020302
Arizona AZ 2 1,246,471,000 0.0160453
District of Columbia DC 2 2,030,075,000 0.0098519
Iowa IA 2 1,521,601,000 0.0131441
Nevada NV 2 156,154,000 0.1280787
West Virginia WV 2 131,353,000 0.1522615
Deleware DE 1 175,392,000 0.0570151
Indiana IN 1 1,561,573,000 0.0064038
Louisiana LA 1 1,040,335,000 0.0096123
Mississippi MS 1 255,328,000 0.0391653
Nebraska NE 1 509,125,000 0.0196415
New Mexico NM 1 738,912,000 0.0135334
Rhode Island RI 1 923,699,000 0.010826
Vermont VT 1 519,525,000 0.0192484
Alaska AK 0 64,920,000 0
Arkansas AR 0 439,598,000 0
Idaho ID 0 61,705,000 0
Montana MT 0 351,502,000 0
New Hampshire NH 0 681,141,000 0
North Dakota ND 0 93,566,000 0
Oklahoma OK 0 567,633,000 0
South Carolina SC 0 810,157,000 0
South Dakota SD 0 90,084,000 0
Wyoming WY 0 48,533,000 0
No. of Vials
Figure 2. Table of Absolute and Normalized hESC Distribution Patterns, by State
Each state, including the District of Columbia, are ranked and coded according to their passed hESC
policy and/or funding decisions, number of hESC vials received, and NIH funding capacity. States are
designated as ‘‘first category’’ (green, italics) if the state has passed legal measures to reduce barriers
to hESC research or to provide research funding. Second category states (black) are those which do
not meet the criteria to be considered first category. States are also classified into quartiles according
to their cumulative vial shipments received and NIH funding awarded (see text for more details). The
top quartile, ‘‘high vial’’ states, is indicated in blue, and ‘‘high NIH’’ states are highlighted in purple. The
total number of vials received was also normalized against the NIH funding dollars per state, and
the top quartile states by this measure are indicated in orange text.
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Island) have taken explicit steps to expand
the reach of stem cell science beyond
federal restrictions and, thus, fall under
our first category. Two-by-two contin-
gency tables revealsignificantassociations
between supportive policies and high ship-
ment volumes (Fisher’s exact test, p =
0.003). Thatdifferenceappears tobedriven
by second category states that receive few
cell lines. The relatively even split between
first and second category states in the top
quartile of hESC recipients suggests that
extensive research capacity might
compensate for lack of policies permitting
or encouraging hESC research.
We address the research capacity
question by roughly classifying states
based on cumulative NIH funding. We
consider states in the top quartile for
cumulative NIH obligations to have high
research capacity. Of the second cate-
gory states that lack supportive policies,
five are both high research capacity
and high vial destinations (Michigan,
North Carolina, Pennsylvania, Texas,
and Washington). One high research
capacity but second category state
(Ohio) received few vials, yet two states
with lower research capacity (Virginia
and Wisconsin) are top quartile destina-
tions for cell lines. The association
between high research capacity and
high demand for cell lines is significant
(p < 0.001) for second category states,
but not for first category states (p =
0.088). In other words, when it comes to
demand for hESC lines, research capacity
trumps supportive state policy.
On the other hand, creating a fertile
hESC research environment is not suffi-
cient to spur demand. Consider New
Jersey. The state was the second to
pass legislation explicitly making hESC
research legal and the first to appropriate
funds for hESC research but reaches the
top quartile on neither absolute nor rela-
tive measures of stem cell demand. This
might be attributed to its relatively low
research capacity, as gauged by NIH
funding levels. In contrast, Ohio has high
research capacity, yet is neither a first
category nor a high vial state. This
suggests that infrastructure alone is also
insufficient.
Through the end of 2007, we find that
U.S.-based hESC research has been
steadily increasing. It is also clear that
federal funding restrictions have not
uniformly chilled hES research in the U.S.
We demonstrate that, at least through
formal mechanisms, WiCell distributed
more lines within the United States than
HSCI. In contrast, pride of place is
reversed for non-U.S. cell line distribu-
tions. Moreover, over a 4 year period,
HSCI distributed more lines than WiCell
did over an 8 year period.
Policy and research capacity also play
an important role. Our findings suggest
that liberalizing policies regarding stem
cell research at the state level does not
ensure increased activity in hESC
research. In sum, our analyses imply (1)
that liberalizing policies may not be suffi-
cient to spur hESC cell research in the
absence of research funding, (2) that
liberal policies may not be necessary to
increase hESC line demand where there
biomedical research infrastructure is
significant, and (3) that actively restrictive
policies may be sufficient to slow the
field’s growth even when there is a history
of significant biomedical research. Even in
the wake of a newly supportive federal
funding environment, policymakers
should note that, before embarking on
legislative and fundraising campaigns,
the complexities of hESC research do
not stop at the laboratory door, but carry
across state lines and national borders
as researchers endeavor to expand
knowledge on one of biology’s most
promising frontiers.
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